The Centers for Medicare & Medicaid Services proposal to cap certain Medicaid payment arrangements is a direct challenge to the financing structures states and providers have increasingly used to support Medicaid reimbursement, especially in managed care.

The new living-donor prize challenge from the Department of Health and Human Services is a useful signal, but the signal matters more than the purse. The federal government is implicitly acknowledging that living kidney donation has not been held back by a lack of goodwill or a lack of clinical capability.

The April 14 sentencing of a Florida nursing assistant in an $11.4 million orthotic-brace fraud scheme is easy to treat as a familiar enforcement item. According to the Department of Justice, the defendant used a Florida durable medical equipment supplier to bill Medicare for braces that beneficiaries did not request or need, while concealing true ownership and relying on illegal kickbacks to obtain signed doctors’ orders, as outlined in the April 14 sentencing announcement.

The Centers for Medicare & Medicaid Services is using its 2026 proposed rule on interoperability and drug prior authorization to do more than shorten approval timelines.

The latest CMS rate notice is easy to misread. On paper, the agency is still increasing payments to Medicare Advantage plans in 2027. In substance, it is drawing a sharper distinction between legitimate clinical risk and revenue built on documentation tactics that have long inflated the program’s economics.

Administrative reshuffles inside HHS usually land as management trivia. This one does not. The department’s March 31, 2026 decision to return enterprise technology, data, and AI leadership to the Office of the Chief Information Officer while restoring the Office of the National Coordinator for Health Information Technology to a narrower health IT policy role arrives at a point when governance failures are no longer abstract.

The latest move from the Centers for Medicare & Medicaid Services will be easy to underestimate because it sounds so administrative. The newly finalized health care claims attachments rule deals with documentation, transaction standards, and electronic signatures, not a flashy care model or a breakthrough therapy. Yet it may prove to be one of the more important healthcare modernization actions in years precisely because it aims at a part of the system that has remained stubbornly primitive long after the industry declared itself digital.

The federal case against Anchorage rheumatologist Claribel Tan should not be read as a routine fraud prosecution with unusually vivid facts. In a March 17 sentencing release from the U.S. Attorney’s Office for the District of Alaska, the Department of Justice said the scheme involved more than $12.5 million in health care fraud, more than $4.2 million in tax loss, and conduct that stretched across 15 years. What makes the case editorially important is not only the money. It is the allegation that the fraud was built into treatment itself.